The phase II/III trial NRG-BN007 (NCT04396860) [68] compared the usual treatment of RT and temozolomide to RT in combination with IT (ipilimumab and nivolumab) for treating patients with newly diagnosed unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) GBM. The gene discussed is MGMT; the disease is glioblastoma.